* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Orbitomaxillary mucormycosis (zygomycosis) and the surgical
Survey
Document related concepts
Onchocerciasis wikipedia , lookup
Hepatitis C wikipedia , lookup
Hepatitis B wikipedia , lookup
Leptospirosis wikipedia , lookup
Dirofilaria immitis wikipedia , lookup
Trichinosis wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Marburg virus disease wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Sarcocystis wikipedia , lookup
Neonatal infection wikipedia , lookup
Schistosomiasis wikipedia , lookup
Oesophagostomum wikipedia , lookup
Transcript
REVIEW 10.1111/j.1469-0691.2009.02989.x Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon A. D. Rapidis Department of Maxillofacial Surgery, Greek Anticancer Institute, St. Savvas Hospital, Athens, Greece Abstract Rhinocerebral or rhino-orbitocerebral (mucormycosis) zygomycosis (ROCZ) usually occurs among patients with poorly controlled diabetes mellitus (especially those with ketoacidosis), solid malignancies, iron overload or extensive burns, in patients undergoing treatment with glucocorticosteroid agents, or in patients with neutropenia related to haematologic malignancies. The disease process starts with inhalation of the fungus into the paranasal sinuses. The fungus may spread to invade the palate, sphenoid sinus, cavernous sinus, orbits or cranially to invade the brain. Pain and swelling precede oral ulceration and the resulting tissue necrosis can result in palatal perforation. Infection can sometimes extend from the sinuses into the mouth and produce painful, necrotic ulcerations of the hard palate. If untreated, infection usually spreads from the ethmoid sinus to the orbit, resulting in the loss of extraocular muscle function and proptosis. Surgical treatment includes the resection of involved tissues of the face, including skin and muscle, any skin of the nose that is involved, maxillary and ethmoid sinuses, necrotic tissue of the temporal area and infratemporal fossa, and orbital exenteration. The keys to successful therapy include suspicion of the diagnosis and early recognition of the signs and symptoms, correction of underlying medical disorders such as ketoacidosis, and aggressive medical and surgical intervention. Keywords: Maxillectomy, mucormycosis, orbital exenteration, zygomycosis Clin Microbiol Infect 2009; 15 (Suppl. 5): 98–102 Corresponding author and reprint requests: A. D. Rapidis, Department of Maxillofacial Surgery, Greek Anticancer Institute, St. Savvas Hospital, 171 Alexandras Avenue, Athens 115 22, Greece E-mail: [email protected] Introduction Zygomycetes have a wide geographical distribution, are all thermo-tolerant, and utilize a variety of nutritional substrates. In nature, they are found in the soil, animal faeces and decaying plant materials [1,2]. They spread by the production of sporangiospores that are released into the environment as airborne propagules. Humans are usually resistant to the disease because Mucorales fungi are ubiquitous in the environment. Nosocomial infections can occur from sporangiospores released through contaminated airconditioning systems or contaminated wound dressings. The fungus exhibits a remarkable affinity for arteries and grows along the internal elastic lamina, causing thrombosis and infarction. Infections occur equally in both sexes, irrespective of age. Mucormycosis, also known as zygomycosis and phycomycosis, was first described by Paultauf in 1885 [3]. The major- ity of cases reported have represented either isolated examples or small, retrospective series. This relative scarcity of cases hinders the drawing of diagnostic and therapeutic conclusions [4]. However, with the increasing prevalence of diabetes and immunosuppressive conditions, mucormycosis has emerged as an important fungal infection. Based on clinical presentation and the involvement of a particular anatomic site, mucormycosis can be divided into at least six clinical categories: (i) rhinocerebral; (ii) pulmonary; (iii) cutaneous; (iv) gastrointestinal; (v) disseminated, and (iv) miscellaneous [5,6]. Risk Factors and Pathophysiology of Rhinocerebral or Rhino-orbitocerebral Zygomycosis Rhinocerebral or rhino-orbitocerebral zygomycosis (ROCZ) usually occurs among patients with poorly controlled diabetes mellitus (especially those with ketoacidosis), solid malignancies, iron overload or extensive burns, or in patients who take glucocorticosteroid agents or have neutropenia related to haematologic malignancies. A recently identified important clinical feature is the increased susceptibility to mucormycosis of patients with elevated available serum iron. It has been ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases CMI Rapidis known for two decades that patients treated with the iron chelator deferoxamine have a markedly increased incidence of invasive mucormycosis [7, 8]. However, it is now clear that iron chelation is not the mechanism by which deferoxamine enables mucormycosis infections. Although deferoxamine is an iron chelator from the perspective of the human host, Rhizopus spp. actually utilize deferoxamine as a siderophore to supply previously unavailable iron to the fungus. Patients with diabetic ketoacidosis are at high risk of developing rhinocerebral mucormycosis. Multiple lines of evidence support the conclusion that patients with systemic acidosis have elevated levels of available serum iron, probably as a result of the release of iron from binding proteins in the presence of acidosis [9]. Neutropenia is another significant risk factor. The correction of neutropenia with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) is important to improve outcome. A breakthrough in the management of zygomycosis in patients with neutropenia was recently achieved with empirical voriconazole therapy in the absence of amphotericin B (AmB) [10,11]. Initiation of early and appropriate antifungal administration and, if required, discontinuation of steroids or deferoxamine is advisable [12]. Rhinocerebral mucormycosis continues to be the most common form of the disease, accounting for between onethird and one-half of all cases of mucormycosis. Approximately 70% of rhinocerebral cases (occasionally referred to as craniofacial cases) occur in diabetes patients with ketoacidosis. More rarely, rhinocerebral mucormycosis has also occurred in patients who have received a solid organ transplant or those with prolonged neutropenia. Recently, rhinocerebral disease has become an increasing problem in patients undergoing haematopoietic stem cell transplantation. These cases have largely been associated with steroid use for graft vs. host disease [13]. Infection with Zygomycetes can be acquired by inhalation, ingestion or the deposition of spores in wounds. The fungi give rise to pathogenic lesions as a result of invasion and growth within the lumen and walls of major blood vessels, with ensuing thromboembolism resulting in ischaemia and tissue necrosis. Agents of zygomycosis have a predilection for the internal elastic lamina of the arterial blood vessels and spread by angioinvasion. The disease process in the ROCZ form probably starts with the inhalation of the fungus into the paranasal sinuses. Upon germination, the fungus may spread inferiorly to invade the palate, posteriorly to invade the sphenoid sinus and beyond into the cavernous sinus, laterally to involve the orbits, or cranially to invade the brain. The fungus has a propensity to grow along the elastic lamina of the blood vessels, dissecting the lamina away from the Surgical approaches to orbitomaxillary mucormycosis 99 media. This direct invasion and dissection by the fungus causes extensive endothelial damage, resulting in thrombus formation and ischaemia to the surrounding tissues. The infarcted tissue creates an environment that promotes fungal proliferation and the resultant poor vascular supply prevents systemic medical therapy from eradicating the fungus. The nasal and sinus walls are invaded via these vessels and the orbit is invaded secondarily via freely communicating foramen and venous channels. The fungus invades the cranium through either the orbital apex or the cribriform plate of the ethmoids and ultimately kills its host [14,15]. Clinical Symptoms and Signs The initial symptoms of ROCZ are consistent with either sinusitis or periorbital cellulitis and include eye or facial pain and facial numbness, followed by the onset of conjunctival suffusion, blurry vision and soft tissue swelling. Symptoms that may suggest mucormycosis in susceptible individuals include multiple cranial nerve palsies, unilateral periorbital facial pain, orbital inflammation, eyelid oedema, blepharoptosis, proptosis, acute ocular motility changes, internal or external ophthalmoplegia, headache or acute vision loss. Fever is variable and may be absent in up to half of the cases. White blood cell counts are typically elevated, as long as the patient has functioning bone marrow [16,17]. Upon visual inspection, infected tissue may appear normal during the earliest stages of spread of the fungus. Infected tissue then progresses through an erythematous phase, with or without oedema, before the onset of a violaceous appearance and, finally, the development of a black, necrotic eschar as the blood vessels become thrombosed and tissue infarction occurs. Palatal involvement is usually the result of the direct extension of disease from the maxillary sinus and in the distribution of the sphenopalatine and greater palatine arteries. Pain and swelling precede oral ulceration, and the resulting tissue necrosis can result in palatal perforation. Infection can sometimes extend from the sinuses into the mouth and produce painful, necrotic ulcerations of the hard palate. If untreated, infection usually spreads from the ethmoid sinus to the orbit, resulting in loss of extraocular muscle function and proptosis. Marked chemosis may also be seen. The infection may rapidly extend into the neighbouring tissues [18]. Cranial nerve findings represent extensive infection and signal a grave prognosis. Progressive vision loss, and ultimately blindness, may result from involvement of the optic nerve, from arterial invasion resulting in infarction, or from ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 98–102 100 Clinical Microbiology and Infection, Volume 15, Supplement 5, October 2009 cavernous sinus thrombosis. Cranial nerves V and VII may also be affected, resulting in ipsilateral loss of facial sensation, ptosis and pupillary dilation. Infection can also spread posteriorly from either the orbit or sinuses to the central nervous system (CNS). A bloody nasal discharge may be the first sign that infection has invaded through the turbinates and into the brain. When there is extensive CNS involvement, the angioinvasive nature of the fungus may result in cavernous sinus thrombosis and internal carotid artery encasement and thrombosis, with resulting extensive cerebral infarctions. Occasionally, cerebral vascular invasion may lead to haematogenous dissemination of the infection, with or without development of mycotic aneurysms [19]. Radiographic Diagnostic Methodology Preoperative contrast-enhanced computed tomography (CT) is useful in defining the extent of the disease. Scans show the oedematous mucosa, fluid filling the ethmoid sinuses, and destruction of periorbital tissues and bony margins. Although sinus CT is the preferred imaging modality, bony destruction is often seen only late in the course of the disease after softtissue necrosis has already occurred [20]. Magnetic resonance imaging (MRI) is useful in identifying the intradural and intracranial extent of the disease, cavernous sinus thrombosis, or thrombosis of the cavernous portion of the internal carotid artery. Perineural spread of the disease can also be demonstrated with contrast-enhanced MRI scans. Although evidence of infection of the soft tissues of the orbit may sometimes be seen by CT scan, MRI is more sensitive when soft tissue lesions are depicted. However, patients with early ROCZ may have normal MRI and CT scans and surgical exploration with biopsy of the areas of suspected infection should always be performed in high-risk patients. Given the limitations of imaging studies, diagnosing mucormycosis almost always requires histopathological evidence of fungal invasion of the tissues [21]. There are no reliable serologic, polymerase chain reaction (PCR)-based or skin tests for mucormycosis. Therefore, the diagnosis should be made by biopsy of infected tissues. The biopsy should demonstrate the characteristic wide, ribbon-like, aseptate hyphal elements that branch at right angles. The organisms are often surrounded by extensive necrotic debris. Other fungi, including Aspergillus, Fusarium and Scedosporium spp., may look similar to the Mucorales on biopsy [22]. However, these moulds have septae, are usually thinner, and branch at acute angles. The genus and species of the infecting organism may be determined by culture of the infected tissue. How- CMI ever, the organism is rarely isolated from cultures of blood, cerebrospinal fluid, sputum, urine, faeces or swabs of infected areas. Surgical Treatment and Antifungal Therapy Aggressive early surgical debridement of the infected craniofacial tissues is the cornerstone of successful treatment of ROCZ mucormycosis. This includes resection of involved tissues of the face, including skin and muscle, any skin of the nose that is involved, maxillary and ethmoid sinuses, necrotic tissue of the temporal area and infratemporal fossa, and orbital exenteration. Orbital exenteration may be life-saving in the presence of active fungal invasion of the orbit and should be considered for an actively infected orbit with a blind, immobile eye. It has been considered helpful even after intracranial spread has occurred. Whether or not to perform orbital exenteration is the most difficult decision in the surgical management of orbital mucormycosis because the procedure may represent a life-saving measure achieved at the cost of permanent mutilation [23]. Surgical debridement usually proceeds quickly because of an almost bloodless field. An aggressive surgical approach appears to enhance survival. The keys to successful therapy include suspicion of the diagnosis with early recognition of the signs and symptoms, correction of underlying medical disorders such as ketoacidosis, and aggressive medical and surgical intervention [24]. The use of all available therapeutic modalities in the treatment of this often fatal infection, including intravenous liposomal AmB and hyperbaric oxygen in addition to the aggressive surgical debridement, are mandatory. Treatment with AmB at the highest tolerable dose is necessary. The use of AmB is limited by frequent side-effects, the most important of which is its dose-limiting nephrotoxicity. Most of the negative side-effects can be avoided by using lipid preparations of AmB [25]. This lipid-based formulation increases circulation time and alters the biodistribution of the associated AmB. Because drugs complexed with lipid vehicles remain longer in the vasculature, they are able to localize and reach greater concentrations in tissues with increased capillary permeability (i.e. tissues in which infection and inflammation are present) compared with regions of normal tissue, which are essentially impermeable to lipidcomplexed drugs [26]. This method of increasing the localization of drugs to diseased sites is referred to as ‘passive targeting’. It enhances delivery of the agent to the fungi, infected organs and phagocytes with lower toxicity, while maintaining antifungal efficacy by ensuring significantly higher sustained tissue levels of the drug. Within these sites, drug ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 98–102 CMI Rapidis release occurs through the action of lipases from surrounding inflammatory cells. The lipid formulations may also enable better solubility into the CNS. The cerebrospinal fluid penetration of conventional AmB is known to be poor and, although the concentration of lipid-based AmB in brain tissue remains unknown, studies describe its successful use in cryptococcal meningitis [27, 28]. Furthermore, the lethal dose (LD50) of lipid-based AmB is approximately 10–15 times higher than that of conventional AmB and has substantially reduced renal toxicity. Thus, the lipid formulations are ideally suited for therapy against infections such as ROCZ, which require large doses of drug given for long periods of time [29]. The recommended dose of liposomal AmB is 5 mg/kg/day prepared as a 1 mg/mL infusion and delivered at a rate of 2.5 mg/kg/h. There are an increasing number of reports of salvage posaconazole therapy for refractory mucormycosis [14]. Successful outcomes of posaconazole administered in conjunction with AmB have been seen in patients with ROCZ mucormycosis and in a heart-kidney transplant patient who failed on amphotericin therapy [30]. Currently, novel regimens for the treatment of mucormycosis include a combination of lipid-based amphotericin plus either an echinocandin or itraconazole or both [25, 31, 32]. In addition, compassionate-use posaconazole is currently available, and its potential for combination therapy with a polyene, caspofungin, or both, is worthy of study. Further data are needed to determine whether posaconazole, alone or in combination with AmB, may be useful for the treatment of mucormycosis. Hyperbaric oxygen has been used as an adjunct to the current therapeutic approach of aggressive surgical debridement, AmB therapy and control of underlying predisposing conditions. Although studies have shown that hyperbaric oxygen exerts a fungistatic effect, its most important effect is to aid neovascularization with subsequent healing in poorly perfused acidotic and hypoxic – but viable – tissue [8]. Hyperbaric oxygen therapy for mucormycosis should consist of exposure to 100% oxygen for 90 min to 2 h at pressures of 2.0–2.5 atmospheres with one or two exposures daily for a total of 40 treatments. Reported toxicities of hyperbaric oxygen include teratogenicity and, rarely, pulmonary or CNS side-effects. Although hyperbaric oxygen is offered by only a few medical facilities, it may be warranted in patients who appear to be deteriorating despite maximal surgical and medical therapy [23, 33]. Surgical approaches to orbitomaxillary mucormycosis 101 can occur within several days to a few weeks, even when appropriate treatment has been instituted. Appropriate management results in a cure in only approximately half of rhinocerebral infections. Given the rapidly progressive nature of rhinocerebral mucormycosis and the marked increase in mortality when the fungus penetrates the cranium, any diabetes patient with a headache and visual changes is a candidate for prompt evaluation which should include imaging studies and nasal endoscopy to rule out mucormycosis. Published case series continue to support the need for surgical debridement to optimize outcomes [34]. For example, in a case series totalling 49 patients with rhinocerebral mucormycosis, the mortality rate was 70% in cases treated with antifungal agents alone compared with 14% in cases treated with antifungal agents plus surgery [35]. Similarly, in a combined series of rhinocerebral, cutaneous and pulmonary mucormycosis, 11 of 17 (65%) patients treated with surgery plus antifungal agents survived the infection, compared with none of seven (0%) patients treated with antifungal agents alone [36]. The nature of the underlying disease and the reversibility of the immune dysfunction are also important determinants of survival. One study showed that 75% of patients with rhinocerebral disease who had no underlying immune compromise survived, whereas 60% of those with diabetes and only 20% of patients with other immunocompromised states were cured. Conclusions The overall survival rate of patients with mucormycosis is approximately 50%, although survival rates of up to 85% have been reported more recently [27]. Much of the variability in outcome is due to the various forms of the disease. Rhino-orbitocerebral mucormycosis has a higher survival rate than does pulmonary or disseminated mucormycosis because the rhinocerebral disease can frequently be diagnosed earlier and the most common underlying cause, diabetic ketoacidosis, can be treated readily. By contrast, pulmonary mucormycosis has a high mortality (65% at 1 year) because it is difficult to diagnose and it frequently occurs in neutropenic patients [11]. Reconstruction should be delayed to ensure that the patient survives, that the infection is completely cleared and that the remaining tissue is healthy [37]. Subsequent Clinical Course and Prognosis Transparency Declaration Mucormycosis is the most acutely fatal fungal infection in humans, with mortality rates of 15–34% [4, 23, 26]. Death The author declares no conflicts of interest. ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 98–102 102 Clinical Microbiology and Infection, Volume 15, Supplement 5, October 2009 References 1. Ameen M, Arenas R, Martinez-Luna E, Reyes M, Zacarias R. The emergence of mucormycosis as an important opportunistic fungal infection: Five cases presenting to a tertiary referral center for mycology. Int J Dermatol 2007; 46: 380–384. 2. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1–15. 3. Paultauf A. Mycosis mucorina. Arch Pathol Anat 1885; 102: 543. 4. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569. 5. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: A retrospective clinical study of 37 cases. Gimema infection program (gruppo italiano malattie ematologiche maligne dell’adulto). Br J Haematol 1997; 99: 331–336. 6. Nosari A, Oreste P, Montillo M et al. Mucormycosis in hematologic malignancies: An emerging fungal infection. Haematologica 2000; 85: 1068–1071. 7. Islam MN, Cohen DM, Celestina LJ, Ojha J, Claudio R, Bhattacharyya IB. Rhinocerebral zygomycosis: An increasingly frequent challenge: Update and favorable outcomes in two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: e28–34. 8. Garcia-Covarrubias L, Bartlett R, Barratt DM, Wassermann RJ. Rhino-orbitocerebral mucormycosis attributable to apophysomyces elegans in an immunocompetent individual: Case report and review of the literature. J Trauma 2001; 50: 353–357. 9. Hosseini SM, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol 2005; 262: 932–938. 10. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP Voriconazoleassociated zygomycosis: A significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15: in press. 11. Rutar T, Cockerham KP. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 2006; 142: 187–188. 12. Orguc S, Yuceturk AV, Demir MA, Goktan C. Rhinocerebral mucormycosis: Perineural spread via the trigeminal nerve. J Clin Neurosci 2005; 12: 484–486. 13. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207–214. 14. Petrikkos G, Skiada A, Sambatakou H et al. Mucormycosis: Ten-year experience at a tertiary-care center in greece. Eur J Clin Microbiol Infect Dis 2003; 22: 753–756. 15. Uckay I, Chalandon Y, Sartoretti P et al. Invasive zygomycosis in transplant recipients. Clin Transplant 2007; 21: 577–582. 16. O’Neill BM, Alessi AS, George EB, Piro J. Disseminated rhinocerebral mucormycosis: A case report and review of the literature. J Oral Maxillofac Surg 2006; 64: 326–333. 17. Cheema SA, Amin F. Five cases of rhinocerebral mucormycosis. Br J Oral Maxillofac Surg 2007; 45: 161–162. 18. Tugsel Z, Sezer B, Akalin T. Facial swelling and palatal ulceration in a diabetic patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 630–636. 19. Liang KP, Tleyjeh IM, Wilson WR, Roberts GD, Temesgen Z. Rhinoorbitocerebral mucormycosis caused by apophysomyces elegans. J Clin Microbiol 2006; 44: 892–898. CMI 20. Franquet T, Gimenez A, Hidalgo A. Imaging of opportunistic fungal infections in immunocompromised patient. Eur J Radiol 2004; 51: 130–138. 21. Mnif N, Hmaied E, Oueslati S et al. [imaging of rhinocerebral mucormycosis]. J Radiol 2005; 86: 1017–1020. 22. Ghadiali MT, Deckard NA, Farooq U, Astor F, Robinson P, Casiano RR. Frozen-section biopsy analysis for acute invasive fungal rhinosinusitis. Otolaryngol Head Neck Surg 2007; 136: 714–719. 23. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517–525. 24. Bengel D, Susa M, Schreiber H, Ludolph AC, Tumani H. Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rrna gene sequence. Eur J Neurol 2007; 14: 1067–1070. 25. Spellberg B, Fu Y, Edwards JE, Jr., Ibrahim AS. Combination therapy with amphotericin b lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830–832. 26. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653. 27. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res 2007; 38: 90–93. 28. Richardson M. Ambisome: Adds to the body of knowledge and familiarity of use. Acta Biomed 2006; 77 (Suppl 4): 3–11. 29. Schutz P, Behbehani JH, Khan ZU et al. Fatal rhino-orbito-cerebral zygomycosis caused by apophysomyces elegans in a healthy patient. J Oral Maxillofac Surg 2006; 64: 1795–1802. 30. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51: 73–77. 31. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin b. Haematologica 2005; 90: ECR39. 32. Nivoix Y, Zamfir A, Lutun P et al. Combination of caspofungin and an azole or an amphotericin b formulation in invasive fungal infections. J Infect. 2006; 52: 67–74. 33. Fairley C, Sullivan TJ, Bartley P, Allworth T, Lewandowski R. Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient. Ophthalmology 2000; 107: 555–558. 34. Tidwell J, Higuera S, Hollier LH, Jr. LH, Facial reconstruction after mucormycosis in an immunocompetent host. Am J Otolaryngol 2005; 26: 333–336. 35. Talmi YP, Goldschmied-Reouven A, Bakon M et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg 2002; 127: 22–31. 36. Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino-orbital mucormycosis without exenteration: The use of multiple treatment modalities. Ophthal Plast Reconstr Surg 2001; 17: 62–66. 37. Lari AR, Kanjoor JR, Vulvoda M, Katchy KC, Khan ZU. Orbital reconstruction following sino-nasal mucormycosis. Br J Plast Surg 2002; 55: 72–75. ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 98–102